Titolo	Data di pubblicazione	Autore(i)
1	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study.	2011	Valenti L; Moscatiello S; Vanni E; Fracanzani AL; Bugianesi E; Fargion S; Marchesini G.
2	Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease	2014	Chiara Rosso; Ester Vanni; Lavinia Mezzabotta; Roberto Gambino; Francesca Saba; Federico Salomone; Ramy Ibrahim Kamal Jouness; Melania Gaggini; Emma Buzzigoli; Chiara Saponaro; Fabrizia Carli; Gian Paolo Caviglia; Maria Lorena Abate; Antonina Smedile; Mario Rizzetto; Maurizio Cassader; Amalia Gastaldelli; Elisabetta Bugianesi
3	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: mith or reality?	2016	Vanni, Ester; Bugianesi, Elisabetta; Saracco, Giorgio
4	The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?	2009	Vanni E; Bugianesi E.
5	The Combination of Liver Stiffness Measurement and NAFLD Fibrosis Score Improves the Nonivasive Diagnostic Accuracy for Severe Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease	2013	S. Petta; E. Vanni; E. Bugianesi; V. Di Marco; C. Camma; MR Barcellona; D. Cabibi; L. Mezzabotta; A. Craxi
6	Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in NASH.	2015	Donati, B; Vanni, E; Dongiovanni, P; Iavarone, M; Rametta, R; Rosso, C; Carnelutti, A; Petta, S; Fracanzani, Al; Reeves, Hl; Dofour, Jf; Miele, L; Anstee, Q; Bugianesi, E; Soardo, G; Fargion, S; Valenti, L
7	A "systems medicine" approach to the study of non-alcoholic fatty liver disease.	2016	Petta, S; Valenti, L; Bugianesi, Elisabetta; Targher, G; Bellentani, S; Bonino, F; Ferrannini, E; Loguercio, C; Lonardo, A; Marra, F; Mancini, M; Miele, L; Nobili, V; Svegliati Baroni, G; Alessandro, F; Ballestri, S; Brunetto, Mr; Coco, B; Grieco, A; Fargion, S; Kondili, L; Nascimbeni, F; Prinster, A; Romagnoli, D; Taddei, S; Vanni, Ester; Vella, S.
8	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.	2015	Vanni, E; Marengo, A; Mezzabotta, L; Bugianesi, E.
9	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C	2009	Vanni E; Abate ML; Gentilcore E; Hickman I; Gambino R; Cassader M; Smedile A; Ferrannini E; Rizzetto M; Marchesini G; Gastaldelli A; Bugianesi E.
10	Serum free fatty acid composition is associated with different degrees of fibrosis.	2014	R. Gambino; N. Alemanno; S. Pinach; F. Saba; L. Mezzabotta; C. Rosso; E. Vanni; E. Bugianesi; M. Cassader
11	Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease	2014	Paul Angulo;Jacob George;Christopher P. Day;Ester Vanni;Lee Russell;Anna C. De la Cruz;Hammad Liaquat;Lavinia Mezzabotta;Eun Lee;Elisabetta Bugianesi
12	THE ROLE OF ANTI-IFI16 ANTIBODIES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD)	2017	Astegiano, M.; Vanni, E.; Finocchiaro, F.; Vernero, M.; Ribaldone, D.; Reggiani, S.; Caviglia, G.; De Andrea, M.; Caneparo, V.; Landolfo, S.; Gariglio, M.; Smedile, A.; Pellicano, R.
13	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes	2008	Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S.
14	Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity	2011	Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S.
15	Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity	2009	A.L. Fracanzani; L. Valenti; E. Bugianesi; E. Vanni; L. Miele; C. Bertelli; E. Fatta; A. Grieco; G. Marchesini; S. Fargion
16	Risk factors for metabolic syndrome after liver transplantation: what has changed over time	2015	Vanni, E.; Younes R; Mirabella, S.; Marengo, A.; Milan, A.; Rosso, C.; Boano, V.; Mosso, E.; Di Stefano, C.; Nada, E.; Mezzabotta, L.; Rizzetto, M.; Salizzoni, M.; Romagnoli, R.; Bugianesi, E.
17	Risk factors for arterial hypertension after liver transplantation	2018	Di Stefano, Cristina*; Vanni, Ester; Mirabella, Stefano; Younes, Ramy; Boano, Valentina; Mosso, Elena; Nada, Elisabetta; Milazzo, Valeria; Maule, Simona; Romagnoli, Renato; Salizzoni, Mauro; Veglio, Franco; Milan, Alberto
18	Response to Dr. Sertoglu and Colleagues	2015	S. Petta; E. Vanni; A. Craxì
19	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver	2004	Bugianesi E; Manzini P; D'Antico S; Vanni E; Longo F; Leone N; Massarenti P; Piga A; Marchesini G; Rizzetto M
20	Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients.	2014	C. Saponaro; E. Vanni; M. Gaggini; C. Rosso; L. Mezzabotta; R. Gambino; E. Buzzigoli; F. Carli; M.L. Abate; F. Saba; F. Salomone; G.P. Caviglia; A. Smedile; M. Rizzetto; M. Cassader; E. Bugianesi; A. Gastaldelli